NEW YORK ─ Infectious disease point-of-care diagnostic test company Talis Biomedical on Friday filed with the US Securities and Exchange Commission to go public on the Nasdaq.
Menlo Park, California-based Talis has not priced the offering but said in its Form S-1 that it plans to sell about 42.7 million shares of its Series 1 convertible preferred stock. The firm said that underwriters for the deal have a 30-day option to purchase additional shares of common stock.
JP Morgan, Bank of America Securities, and Piper Sandler are the joint bookrunners on the deal.